Samsung Bioepis considering takeover of Biogen's unit: reports
Biosimilaires: Samsung Bioepis se renforce sur un marché porteur - actualités- Pharmaceutiques
Le bénéfice de Biogen fait plus que doubler suite à la vente de la participation de Samsung Bioepis -Le 20 juillet 2022 à 13:09 | Zonebourse
Samsung Biologics Prepares for Budding Alzheimer's Treatment Deals
Samsung s'associe à Biogen Idec
Samsung Group reportedly in talks to acquire Biogen < Pharma < Article - KBR
Samsung Bioepis ponders acquiring unit from U.S. partner Biogen
Biogen gains ophthalmology biosimilar candidates for Lucentis, Eylea in deal with Samsung Bioepis
Company News | Newsroom | SAMSUNG BIOLOGICS
Biogen takes on Lucentis, Eylea biosimilars from Samsung joint venture - PMLiVE
Biogen Recoups Much-Needed $2.3B with Sale of Samsung Bioepis Stake | BioSpace
Biosimilaires : Samsung Bioepis conclut un nouvel accord de commercialisation avec Biogen | MyPharma Editions
Biogen to sell equity stake in Samsung Bioepis joint venture for up to $2.3B - Drug Discovery and Development
Biogen to sell stake in Samsung Bioepis JV for up to $2.3bn
Biogen Ups Investment in Biosimilar Drug Maker Samsung Bioepis by $700 Million | BioSpace
Samsung in Talks to Buy Alzheimer's Drug Maker Biogen for $42 Billion: Report | Technology News
Biosimilaires : Biogen se déleste de Samsung Bioepis
Biogen Poised for Pipeline Growth, Samsung Eyes New Drug Expansion after $2.3B Joint Venture Deal
Biogen — Wikipédia
Samsung BioLogics says report on Biogen deal talks untrue | Fox Business
Biogen/Samsung Takeover - Deal Or No Deal?
Biogen of US might reap W2tr from Samsung Bioepis call option
Samsung Bioepis : ventes record en Europe au T1 | AGENCE DE PRESSE YONHAP
Samsung Biologics buys out Biogen in biosim venture for US$2.3B | HealthCare Middle East & Africa Magazine
